Health
Antibiotic
Antibiotic Resistance
Also known as antibacterial drug, anti-bacterial agent, antibacterial agent, anti-bacterial agents
Antibiotics are the drugs that turned deadly infections into minor problems, but bacteria are fighting back by evolving into 'superbugs' the drugs can't kill. We're inventing new ones far slower than the bacteria adapt, so it's a race we're starting to lose. This links to Economics, because drug companies have little incentive to make new antibiotics that don't earn much money, a classic market failure. It also reaches Environment, since farms pump antibiotics into animals, and Mathematics, because slowing resistance is a game-theory problem of getting everyone to use the drugs carefully instead of grabbing the short-term win.
Key people
- Gladys Lounsbury HobbyAmerican scientist (1910-1993)
- Elizabeth McCoyAmerican microbiologist (1903 – 1978)
- Wilfred van der DonkDutch-American enzymologist and chemical biologist
- Roman Kozlov
Timeline
- 1910The Hoechst company began to market the compound toward the end of 1910 under the name Salvarsan, now known as arsphenamine.
- 1935From 1935 to 1968, 12 new classes were launched.
- 1950The overuse of antibiotics, like penicillin and erythromycin, has been associated with emerging antibiotic resistance since the 1950s.
- 1969However, the number of new classes dropped markedly, with only two new classes introduced between 1969 and 2003.
- 1990Nubian mummies studied in the 1990s were found to contain significant levels of tetracycline.
Read
- Natural AntibioticsM. Clarkshire · 2015Book
- Antibiotics and ChemotherapyO. Gsell · 1953Book
- AntibioticsChristopher Walsh · 2003Book
- Antibiotics and antibiotic resistanceOla Sköld · 2011Book
Listen
- Podcasts "Antibiotic Stewardship"St. Franziskus Hospital MünsterPodcast
- Antibiotic PharmacistAntibiotic PharmacistPodcast
- AntibioticsEmma NylandPodcast
- MMWR Weekly BriefingCENTERS FOR DISEASE CONTROL AND PREVENTIONPodcast
By the numbers
- 73.5Global life expectancy (yrs) — global, 2024 (World Bank)
- 10.1Health spend (% GDP) — global, 2023 (World Bank)
Debates
- Is developing new antibiotics the most effective strategy against resistance?One view: Yes, continuous discovery and development of novel drugs are crucial to combat evolving bacterial threats. · Another: No, focusing on improved hygiene, infection control, and responsible antibiotic stewardship is more sustainable.Open question
- Should antibiotics be available without a prescription in certain situations?One view: Yes, in remote areas or for common, self-limiting infections, it could increase access to care. · Another: No, prescription-only access prevents misuse and overuse, which drives antibiotic resistance.Open question
Glossary
- AntibioticA medicine that kills or slows the growth of specific bacteria.
- BacteriaSingle-celled microorganisms, some of which cause infections and are targeted by antibiotics.
- Antibiotic ResistanceWhen bacteria change over time and become unaffected by antibiotics designed to kill them.
- PathogenAny microorganism, such as bacteria, viruses, or fungi, that can cause disease.
- StewardshipThe responsible use of antibiotics to preserve their effectiveness and slow resistance.
- Broad-spectrumAn antibiotic effective against a wide range of bacterial types.
Careers
Roles this can lead toward
Student research
Published policy papers by One Young India delegates — every delegate leaves published under their own name.
Threads 7
Where this connects to other fields — and why it's worth knowing.
- Markets, Competition & Firms Economics
A brand-new antibiotic is a business nightmare: doctors are told to use it as rarely as possible, and it cures you in days so you never buy more. That's the opposite of the daily pills for chronic disease that drug companies love. So the market barely bothers making them, even as old antibiotics stop working.
- Food & Agriculture Systems Environment
Most antibiotics aren't taken by sick people — they're fed to farm animals to fatten them up. All that use breeds drug-resistant "superbugs." So the medical emergency of antibiotics failing is really a farming story wearing a doctor's coat.
- The Energy Transition Environment
Every time we take an antibiotic, bacteria evolve a little more resistance, so the drug slowly stops working, forever. That means antibiotic power is a finite reserve we're using up, exactly like oil in the ground, except it took evolution millions of years to build. We're burning through it fast and creeping toward 'peak antibiotic,' the point where we start running out.
- Trade, Money & Economies History
Long ago, plague spread along the caravan routes traders traveled. Today the genes that make bacteria immune to our medicines hitch rides on global shipping the same way. So one farm overusing antibiotics can seed an untreatable infection on a whole other continent.
- Incentives & Rational Choice Economics
Drug companies barely make new antibiotics, and it's not laziness, it's math. A great antibiotic must be locked away and used as rarely as possible so germs don't adapt. That makes it the one medicine whose sales collapse precisely because it works so well, so nobody wants to build it.
- Market Failure & Externalities Economics
Every time someone takes an antibiotic, they use up a bit of a shared resource: bacteria that the drug can still kill. Nobody owns it, so nobody protects it. It's a classic case of everyone draining something free until it runs out, and superbugs are the bill.
- Game Theory & Strategy Mathematics
Use your most powerful antibiotic on everything, and bacteria evolve to beat it, leaving you defenseless. So the smart move is to hold it back like a secret weapon in reserve. In this game against germs, restraint beats firepower.